Reuters logo
BRIEF-Alkermes announces initiation of study 217 for ALKS 5461
June 12, 2017 / 11:14 AM / 5 months ago

BRIEF-Alkermes announces initiation of study 217 for ALKS 5461

June 12 (Reuters) - Alkermes Plc

* Alkermes announces initiation of study 217 for ALKS 5461 for treatment of major depressive disorder

* ‍phase 3B study designed to further evaluate ALKS 5461’s potential benefits on mood domains regulated by endogenous opioid modulation​

* ‍Company reiterates plans to submit new drug application to FDA by year-end 2017​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below